Last reviewed · How we verify
Nifedipine XL
At a glance
| Generic name | Nifedipine XL |
|---|---|
| Also known as | Procardia, Procardia XL, Adalat, Adipine, Coracten, Fortipine, Nifedipress, Procardia XL, Adalat XL, Nife-Par |
| Sponsor | Creighton University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safest Choice of Antihypertensive Regimen for Postpartum Hypertension (PHASE3)
- Postpartum Evaluation of Nifedipine and Enalapril for Hypertension (PHASE4)
- Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project (PHASE1)
- Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy
- Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia (NA)
- Treating Postictal Symptoms Using Ibuprofen and Nifedipine (PHASE2)
- Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial (PHASE4)
- Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nifedipine XL CI brief — competitive landscape report
- Nifedipine XL updates RSS · CI watch RSS
- Creighton University portfolio CI